Get the Stockscreener App
1.35
4.65%
0.06
After Hours:
1.35
Evogene Ltd stock is traded at $1.35, with a volume of 128.96K.
It is up +4.65% in the last 24 hours and down -18.18% over the past month.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.
See More
Previous Close:
$1.29
Open:
$1.3
24h Volume:
128.96K
Relative Volume:
0.47
Market Cap:
$9.17M
Revenue:
$5.64M
Net Income/Loss:
$-23.88M
P/E Ratio:
-2.4545
EPS:
-0.55
Net Cash Flow:
$-22.36M
1W Performance:
-1.46%
1M Performance:
-18.18%
6M Performance:
-78.05%
1Y Performance:
-84.25%
1-Day Range:
$1.30
$1.44
1-Week Range:
$1.20
$1.44
52-Week Range:
$1.20
$10.40
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
1.35 | 9.17M | 5.64M | -23.88M | -22.36M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-21 | Initiated | ROTH Capital | Buy |
| Jul-29-21 | Initiated | Aegis Capital | Buy |
| Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
Evogene Ltd. (NASDAQ:EVGN) Position Lessened by BNP Paribas Financial Markets - Defense World
Evogene (NASDAQ:EVGN) Now Covered by StockNews.com - Defense World
Evogene (NASDAQ:EVGN) vs. N2OFF (NASDAQ:NITO) Financial Review - Defense World
Evogene stock touches 52-week low at $1.25 amid market challenges - Investing.com Canada
Evogene stock touches 52-week low at $1.25 amid market challenges By Investing.com - Investing.com South Africa
Minichromosomal Technology in Agriculture Market Size - openPR
Marrone Bio Innovations : Evogene and Marrone Bio Innovations Disclose Positive Results in Insect Control Collaboration - Marketscreener.com
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification - GuruFocus.com
Evogene Schedules Second Quarter 2024 Financial Results Release - The Eastern Progress Online
Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials - The Eastern Progress Online
Evogene stock touches 52-week low at $1.44 amid market challenges - Investing.com Nigeria
Evogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7th, 2024 - GuruFocus.com
Evogene Unit Receives Notice Of Termination Of Licensing Agreement With Corteva For Bio Fungicide Lead Candidates - XM
Evogene Q3 2024 Earnings Preview - MSN
Ventum Financial Issues Pessimistic Forecast for Evogene (TSE:EVGN) Stock Price - Defense World
Evogene Ltd. (NASDAQ:EVGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Evogene Ltd (EVGN) Q3 2024 Earnings Call Highlights: Navigating Challenges and Seizing Opportunities - Investing.com Canada
Evogene Schedules Third Quarter 2024 Financial Results Release - GuruFocus.com
Casterra Announces a Key Milestone in its Operational Expansion - GuruFocus.com
Evogene Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Evogene earnings missed by $0.30, revenue fell short of estimates - Investing.com India
Evogene Reports Third Quarter 2024 Financial Results - The Malaysian Reserve
Evogene: Q3 Earnings Snapshot - San Antonio Express-News
Evogene Sees Revenue Growth and Expands AI Collaboration - TipRanks
SEC Form 424B3 filed by Evogene Ltd - Quantisnow
Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results - Marketscreener.com
Evogene stock hits 52-week low at $1.7 amid market challenges - Investing.com India
Evogene (EVGN) Set to Announce Quarterly Earnings on Thursday - Defense World
Lavie Bio Announces Commercial Expansion of Yalos As Seed Treatment for Soybean - Agribusiness Global
Lavie Bio Announces Commercial Expansion of Yalos as Seed-Treatment for Soybean, Following Successful Field Trials - Krishak Jagat English
Evogene subsidiary Lavie Bio announces commercial expansion of Yalos treatment - TipRanks
Evogene (EVGN) to Report Q3 2024 Results, Hosts Virtual Conference Call Nov 21 | EVGN Stock News - StockTitan
II: Exploring 🧭 TechBio - substack.com
Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design - Krishak Jagat English
Evogene and Google Cloud Partner to Develop AI Foundation Model for Drug Discovery - HIT Consultant
Evogene stock hits 52-week low at $2.13 amid market challenges - Investing.com Australia
500: Something went wrong - Investing.com
Evogene partners with Google Cloud for AI-driven molecule design By Investing.com - Investing.com Australia
Evogene partners with Google Cloud for AI-driven molecule design - Investing.com India
Biomica to Present at Digestive Disease Week (DDW) Conference 20 - GuruFocus.com
Evogene announces collaboration with Google Cloud - MSN
Evogene Ltd Stock (EVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):